Biodistribution of antisense nanoparticles in mammary carcinoma rat model

References

• Adwan, H., Bauerle, T.J., Berger, M.R. (2004). Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther. 11:109–20.
   PubMed Web of Science ®Google Scholar
• Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, A.F., Szabo, M., Cantor, A., Coppola, D., Yeatman, T.J. (2002). Oste-opontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 94:513–21.
   PubMed Web of Science ®Google Scholar
• Alefelder, S., Patel, B.K., Eckstein, F. (1998). Incorporation of terminal phosphorothioates into oligonucleotides. Nucleic Acids Res. 26:4983–8.
   PubMed Web of Science ®Google Scholar
• Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 5:505–15.
   PubMed Web of Science ®Google Scholar
• Bala, I., Hariharan, S., Kumar, M.N. (2004). PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 21:387–422.
   PubMed Web of Science ®Google Scholar
• Bishop, J.S., Guy-Caffey, J.K., Ojwang, J.O., Smith, S.R., Hogan, M.E., Cossum, P.A., Rando, R.F., Chaudhary, N. (1996). Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J Biol Chem. 271:5698–703.
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas, L., Blanchette, J.O. (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 56:1649–59.
   PubMed Web of Science ®Google Scholar
• Brigger, I., Dubernet, C., Couvreur, P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 54:631–51.
   PubMed Web of Science ®Google Scholar
• Cohen, H., Levy, R.J., Gao, J., Fishbein, I., Kousaev, V., Sosnowski, S., Slomkowski, S., Golomb, G. (2000). Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther. 7:1896–905.
   PubMed Web of Science ®Google Scholar
• Cohen-Sacks, H., Najajreh, Y., Tchaikovski, V., Gao, G., Elazer, V., Dahan, R., Gati, I., Kanaan, M., Waltenberger, J., Golomb, G. (2002). Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Ther. 9:1607–16.
   PubMed Web of Science ®Google Scholar
• De Martimprey, H., Vauthier, C., Malvy, C., Couvreur, P. (2009). Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm. 71:490–504.
   PubMed Web of Science ®Google Scholar
• Elazar, V., Adwan, H., Baeuerle, T., Rohekar, K., Golomb, G., Berger, M.R. (2010). Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int J Cancer. 126:1749–60.
   PubMed Web of Science ®Google Scholar
• Farokhzad, O.C., Langer, R. (2006). Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev. 58:1456–9.
   PubMed Web of Science ®Google Scholar
• Fattal, E., Barratt, G. (2009). Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol. 157:179–94.
   PubMed Web of Science ®Google Scholar
• Fattal, E., Bochot, A. (2008). State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm. 364:237–48.
   PubMed Web of Science ®Google Scholar
• Frauendorf, C., Hausch, F., Rohl, I., Lichte, A., Vonhoff, S., Klussmann, S. (2003). Internal 32P-labeling of L-deoxyoligonucleotides. Nucleic Acids Res. 31:e34.
   PubMedGoogle Scholar
• Greish, K. (2007). Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 15:457–64.
   PubMed Web of Science ®Google Scholar
• Jaaskelainen, I., Urtti, A. (2002). Cell membranes as barriers for the use of antisense therapeutic agents. Mini Rev Med Chem. 2:307–18.
   PubMed Web of Science ®Google Scholar
• Juliano, R., Alam, M.R., Dixit, V., Kang, H. (2008). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36:4158–71.
   PubMed Web of Science ®Google Scholar
• Juliano, R., Bauman, J., Kang, H., Ming, X. (2009). Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm. 6:686–95.
   PubMed Web of Science ®Google Scholar
• Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., Guise, T.A., Massague, J. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3:537–49.
   PubMed Web of Science ®Google Scholar
• Kurreck, J. (2003). Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem. 270:1628–44.
   PubMedGoogle Scholar
• Ledley, F.D. (1996). Pharmaceutical approach to somatic gene therapy. Pharm Res. 13:1595–614.
   PubMed Web of Science ®Google Scholar
• Li, S.D., Huang, L. (2008). Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 5:496–504.
   PubMed Web of Science ®Google Scholar
• Maeda, H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 41:189–207.
   PubMedGoogle Scholar
• Mahato, R.I., Takakura, Y., Hashida, M. (1997). Development of targeted delivery systems for nucleic acid drugs. J Drug Target. 4:337–57.
   PubMed Web of Science ®Google Scholar
• Rosol, T.J. (2000). Pathogenesis of bone metastases: role of tumor-related proteins. J Bone Miner Res. 15:844–50.
   PubMed Web of Science ®Google Scholar
• Rudland, P.S., Platt-Higgins, A., El-Tanani, M., De Silva Rudland, S., Barraclough, R., Winstanley, J.H., Howitt, R., West, C.R. (2002). Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 62:3417–27.
   PubMedGoogle Scholar
• Sambrook, J.E., Fritsch, E.F., Maniatis, T. (1989). Molecular cloning: A laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory.
   Google Scholar
• Shive, M.S., Anderson, J.M. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 28:5–24.
   PubMed Web of Science ®Google Scholar
• Smith, A.E. (1995). Viral vectors in gene therapy. Annu Rev Microbiol. 49:807–38.
   PubMed Web of Science ®Google Scholar
• Stahel, R.A., Zangemeister-Wittke, U. (2003) Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer. 41(Suppl 1):S81–8.
   PubMedGoogle Scholar
• Tamm, I. (2006). Antisense therapy in malignant diseases: status quo and quo vadis? Clin Sci. 110:427–42.
   PubMed Web of Science ®Google Scholar
• Tamm, I., Wagner, M. (2006). Antisense therapy in clinical oncology: preclinical and clinical experiences. Mol Biotechnol. 33:221–38.
   PubMed Web of Science ®Google Scholar
• Tuck, A.B., Chambers, A.F. (2001). The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 6:419–29.
   PubMed Web of Science ®Google Scholar
• Wang, H., Prasad, G., Buolamwini, J.K., Zhang, R. (2001). Antisense anticancer oligonucleotide therapeutics. Curr Cancer Drug Targets. 1:177–96.
   PubMed Web of Science ®Google Scholar
• Weyermann, J., Lochmann, D., Zimmer, A. (2004). Comparison of antisense oligonucleotide drug delivery systems. J Contr Rel. 100:411–23.
   PubMed Web of Science ®Google Scholar
• White, P.J., Anastasopoulos, F., Pouton, C.W., Boyd, B.J. (2009). Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides. Expert Rev Mol Med. 11:e10.
   PubMed Web of Science ®Google Scholar
• Zendegui, J.G., Vasquez, K.M., Tinsley, J.H., Kessler, D.J., Hogan, M.E. (1992). In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides. Nucleic Acids Res. 20:307–14.
   PubMed Web of Science ®Google Scholar
• Zhang, L., Gu, F.X., Chan, J.M., Wang, A.Z., Langer, R.S., Farokhzad, O.C. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 83:761–9.
   PubMed Web of Science ®Google Scholar